Lonafarnib

Dec 11, 2018

Eiger BioPharmaceuticals Reports on 2018 R&D Day

Dec 03, 2018

Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies

Nov 19, 2018

Eiger to Participate in Piper Jaffray Healthcare Conference

Nov 09, 2018

Eiger Bio Reports Third Quarter 2018 Financial Results

Oct 22, 2018

Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019

Oct 18, 2018

Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference

Oct 16, 2018

Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint

Sep 25, 2018

Eiger BioPharmaceuticals to Participate in Investor Conferences

Sep 04, 2018

Eiger Announces Positive Meeting with FDA on Progeria Program

Aug 10, 2018

Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results

May 16, 2018

Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)

May 16, 2018

Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals